M+QuickMedCalc
Educational reference only. Not a diagnostic tool. See full disclaimer.
CardiologyFriedewald LDL-C

Traditional Friedewald LDL-C Calculator

Reproduce the traditional 1972 Friedewald LDL-C estimate from one same-unit lipid panel, with exact triglyceride boundaries and current-method limitations.

Content updated: View sources

QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.

Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.

Model identity: this page reproduces only the traditional 1972 Friedewald LDL-C equation after one complete, same-unit lipid panel is submitted. It does not calculate Martin/Hopkins or Sampson/NIH LDL-C, identify the method on a laboratory report, classify the result, or determine a goal or treatment.

Use the single unit printed for total cholesterol, HDL-C, and triglycerides on the same lipid panel. The first or unchanged selection preserves entered values; changing to a different unit or clearing the unit clears them rather than reinterpreting numbers.

Enter the reported total cholesterol in the selected unit. Positive ordinary decimals below 1,000,000,000 are supported as a technical display limit, not a healthy or clinical reference range.

Enter HDL-C from the same specimen in the selected unit. Non-negative ordinary decimals below 1,000,000,000 are supported as a technical display limit, not a normal range.

Enter triglycerides from the same specimen in the selected unit. The Friedewald model boundary is strictly below 400 mg/dL or 4.5 mmol/L; being below it does not guarantee accuracy.

About

This page is a Traditional 1972 Friedewald LDL-C Calculator. It uses total cholesterol, HDL-C, and triglycerides from one same-unit lipid panel and reports non-HDL-C, an estimated VLDL-C term, and the historical Friedewald LDL-C estimate. It does not directly measure LDL-C, identify the laboratory method, calculate ASCVD risk, set an LDL-C goal, or choose treatment. [1, 6]

The original study used 448 fasting plasma samples and treated triglycerides divided by 5 as an estimated VLDL-C term, not a measured VLDL-C concentration. The fixed ratio is a historical model assumption; chylomicrons, abnormal VLDL composition, type III dysbetalipoproteinemia, and changing triglyceride composition can make it less representative.[1, 2]

Current guidance prefers modern LDL-C estimation methods for a standard lipid profile in appropriate settings, but this page deliberately does not replace its frozen Friedewald runtime. Martin/Hopkins, extended Martin/Hopkins, Sampson/NIH, direct homogeneous assays, and beta-quantification are different methods and are not silently inferred from this result. [3, 4, 6, 7, 10, 11]

Formula

mg/dL: LDL-C = TC − HDL-C − (TG ÷ 5); non-HDL-C = TC − HDL-C. The TG ÷ 5 term is estimated VLDL-C, not a measurement. [1]
mmol/L: LDL-C = TC − HDL-C − (TG ÷ 2.2); non-HDL-C = TC − HDL-C. The 2.2 divisor is the traditional SI expression. [1]
This runtime accepts TG <400 mg/dL or <4.5 mmol/L only. The 4.5 mmol/L value is a commonly used reduced SI boundary expression, not an infinitely precise conversion of 400 mg/dL. Internal arithmetic is not rounded early, and this page does not convert a submitted panel between units. [1, 6]
Only the traditional fixed-divisor Friedewald model runs here; Martin/Hopkins and Sampson/NIH are described but never calculated. No output is turned into a normal/abnormal label, goal, risk class, or treatment. [10, 11]

Interpretation

LDL-C method comparison

Static method identity; the page never chooses a method from a submitted result.
MethodWhat it doesThis page
Traditional Friedewald [1]Fixed TG divisor of 5 in mg/dL or 2.2 in mmol/L.The only runtime model; TG must be below this page's boundary.
Martin/Hopkins or extended Martin/Hopkins [3, 5]Uses an adjustable TG:VLDL-C factor based on TG and non-HDL-C strata.Described as a modern alternative, never calculated here.
Sampson/NIH [4]A distinct nonlinear equation developed and validated against beta-quantification references, including higher-TG research settings.Not calculated here; its range is not imported into Friedewald validation.
Direct homogeneous LDL-C assay [6, 7]An automated measurement method whose platform, reagents, calibration, low LDL-C, high TG, and unusual lipoproteins can affect comparability.No direct measurement is performed.
Beta-quantification [4, 6]A reference measurement path involving ultracentrifugation and subsequent fraction analysis; it is not the same as a routine direct homogeneous assay.Not executed here.

Why current practice may use another method

The fixed TG:VLDL-C ratio can vary with triglyceride level, non-HDL-C, lipoprotein composition, and low LDL-C. Studies comparing Friedewald with direct or preparative-ultracentrifugation references found method differences that can matter near clinical decision thresholds, without creating a personal correction that this calculator can apply.[2, 5]

The 2026 ACC/AHA guideline prefers Martin/Hopkins or Sampson/NIH over Friedewald for LDL-C estimation from a standard lipid profile, and ADLM guidance emphasizes reporting the actual calculated, direct, or beta-quantification method. The two formal corrections are kept as separate references; this page does not automatically replace the user's selected historical equation. [6, 7, 10, 11]

Fasting, nonfasting, and the triglyceride boundary

The original Friedewald work used fasting plasma data. Modern standard lipid profiles commonly allow fasting or nonfasting collection, but food and other pre-analytic conditions can change triglycerides and therefore affect a fixed-divisor estimate. Certain high-TG or other clinical contexts may call for a fasting repeat; this page neither collects fasting status nor declares a sample valid or invalid.[1, 6, 9]

The runtime boundary is strictly TG <400 mg/dL or <4.5 mmol/L. Being below it permits only the arithmetic and does not guarantee accuracy. At or above it, the model is withheld rather than extended to the higher-TG research range of Sampson/NIH or another method.[1, 4, 6]

What the reported quantities do and do not mean

LDL-C is cholesterol mass estimated within LDL particles; it is not LDL particle number or ApoB. ApoB reflects particle-containing lipoproteins, and one particle can carry different cholesterol amounts, so the measures can be discordant. Non-HDL-C is TC − HDL-C and includes cholesterol in multiple non-HDL lipoprotein classes. Lp(a)-cholesterol can contribute to lipid measurements, but this page does not separate Lp(a)-C or infer ApoB, LDL-P, or Lp(a) from any displayed card.[6, 8]

The estimated VLDL-C term is TG divided by the selected historical divisor, not a measured VLDL-C result. If the submitted arithmetic is zero or negative, the page withholds the estimate instead of clamping it to zero or presenting a negative cholesterol concentration. ADLM guidance supports appropriate lower reporting limits; this behavior is a display-safety and model-compatibility boundary, not a diagnosis.[1, 6, 7]

Clinical contexts not modeled here

Pregnancy, pediatric lipid assessment, familial hypercholesterolemia, familial chylomicronemia, type III dysbetalipoproteinemia, severe hypertriglyceridemia, cholestatic liver disease or LpX, acute illness, diabetes, kidney disease, lipid-lowering therapy, very low LDL-C, and unusual lipoprotein composition may affect method choice or interpretation. This page does not diagnose those conditions, assign normal or abnormal categories, set a personal target, or recommend a medicine or dose. [6, 8, 10]

How to use this page without changing the model

Choose the unit printed for the panel, enter TC, HDL-C, and TG from the same report, and submit explicitly. A unit change clears the numeric fields rather than silently converting them. The result cards expose the subtraction and fixed-divisor term so that a later laboratory comparison can retain the method identity.[1, 6]

Why a laboratory method name matters

A report may identify calculated LDL-C, direct homogeneous LDL-C, or a reference procedure. Those labels describe different measurement or estimation paths. Keep the laboratory's stated method when comparing serial values, and do not treat this historical calculator as a way to reconstruct a missing assay result. [5, 6, 7]

Why this page has no LDL-C target

Contemporary LDL-C and non-HDL-C targets depend on the prevention and disease pathway, overall risk, and clinical history. The four values accepted here cannot establish those conditions, so the page reports transparent arithmetic without a goal, diagnosis, or treatment output.[10, 11]

References

  1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. PMID 4337382.
  2. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62(8):732–739. PMID 23524048. DOI 10.1016/j.jacc.2013.01.079.
  3. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating LDL-C levels from the standard lipid profile. JAMA. 2013;310(19):2061–2068. PMID 24240933. DOI 10.1001/jama.2013.280532.
  4. Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540–548. PMID 32101259. PMCID PMC7240357. DOI 10.1001/jamacardio.2020.0013.
  5. Martin SS, Giugliano RP, Murphy SA, et al. Comparison of LDL-C Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA Cardiol. 2018;3(8):749–753. PMID 29898218. DOI 10.1001/jamacardio.2018.1533.
  6. Cao J, Donato L, El-Khoury JM, et al. ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2024;9:1040–1056. PMID 39225455. DOI 10.1093/jalm/jfae057.
  7. Correction to: ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2025;10(4):1085. PMID 40172951. DOI 10.1093/jalm/jfaf021.
  8. Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496–517. PMID 31855562. DOI 10.1515/cclm-2019-1253.
  9. Nordestgaard BG, Langsted A, Mora S, et al. Fasting Is Not Routinely Required for Determination of a Lipid Profile. Clin Chem. 2016;62(7):930–946. PMID 27235445. DOI 10.1373/clinchem.2016.258897.
  10. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. PMID 41824552. DOI 10.1161/CIR.0000000000001423.
  11. Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153(25):e1447. PMID 42330109. DOI 10.1161/CIR.0000000000001457.

FAQ

Related Calculators

Disclaimer

Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.